Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
protease inhibitor |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX45
|
| gptkbp:brand |
gptkb:Kyprolis
|
| gptkbp:CASNumber |
868540-17-4
|
| gptkbp:chemicalFormula |
C40H57N5O7
|
| gptkbp:contraindication |
hypersensitivity to carfilzomib
|
| gptkbp:developedBy |
gptkb:Onyx_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
0.5–1 hour
|
| https://www.w3.org/2000/01/rdf-schema#label |
carfilzomib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits 20S proteasome
|
| gptkbp:metabolism |
peptidase cleavage
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
11556711
CHEMBL451887 DB08889 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea fatigue thrombocytopenia dyspnea cardiac failure pyrexia |
| gptkbp:UNII |
N2B54237CO
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:Darzalex
|
| gptkbp:bfsLayer |
6
|